BGMHealthcare · Drug Manufacturers - Specialty & Generic

BGM Stock Forecast: BGM Group Ltd. Price Predictions for 2026-2027

Last close, 24 Aug 2026
$0.25
−4.43% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 33 of 100 as at 22 Aug 2026 — in the lower half.

Market cap
$105.1M
Ticker Nerd rank
33 / 100
Median analyst target
Analysts covering
Total return, dividends reinvested
1W
−7.9%
1M
−13.7%
YTD
−93.2%
1Y
−96.9%
From 52W high
−97.9%
From 52W low
0.0%
$0
$12
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

BGM stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores BGM Group Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
33 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
84
Value
76
Size
74
Growth
49
Volatility
45
Accruals
31
Revisions
25
Momentum
16
Issuance
14

Quality (84): The business earns solid, repeatable profits on what it owns.

Issuance (14): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

BGM stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BGM, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$2$4$6$8$10$12Oct 25Jan 26Apr 26Jul 26BGM

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BGM appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

BGM vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 24 Aug 2026, BGM Group Ltd. returned −96.9% against +19.6% for the S&P 500, dividends included.

BGM vs S&P 500, last 12 monthsTotal return, rebased to 100
050100150Oct 25Jan 26Apr 26Jul 26BGMS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

BGM analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

BGM Group Ltd. (BGM) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
15.0×

Cheaper than 47% of US stocks

Price / sales
2.8×

Cheaper than 44% of US stocks

Price / book
0.1×

Cheaper than 90% of US stocks

EV / EBITDA
−4.0×

Cheaper than 77% of US stocks

Growth & margins
Revenue growth (YoY)
88.3%

Higher than 92% of US stocks

Earnings growth (YoY)
Gross margin
Operating margin
−43.8%

Higher than 18% of US stocks

Net margin
−52.6%

Higher than 10% of US stocks

Returns & dividend
Return on equity
−9.3%

Higher than 36% of US stocks

Return on assets
−3.2%

Higher than 34% of US stocks

Dividend yield

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

BGM Group Ltd. (BGM) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • BGM Group Ltd. has a market value of $105.1M and an enterprise value of $44.8M.

  • Shares outstanding: 200.6M.

  • Trailing P/E: 15.0×.

  • BGM Group Ltd. employs 298 people.

market figures as at 24 Aug 2026

Data provided by Twelve Data

Peers

BGM vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
BGMBGM Group Ltd.$105.1M
33
CPIXCumberland Pharmaceuticals, Inc.$114.6M
85
ADCTADC Therapeutics SA$123.5M
73
LFCRLifecore Biomedical, Inc.$170.1M
4
CTORCitius Oncology, Inc.$69.2M
15
OGIOrganigram Global, Inc.$177.3M
40
ZYBTZhengye Biotechnology Holding Ltd.$60.6M
47

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own BGM Group Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Frequently asked questions about BGM stock

How does Ticker Nerd's model rank BGM?

As at 22 Aug 2026, BGM Group Ltd. ranks 33 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (84 of 100).

What is the BGM stock forecast for 2030?

No analyst covering BGM Group Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BGM are extrapolating price history, which says nothing about the business.

How has BGM stock performed over the past year?

BGM Group Ltd. returned -96.9% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does BGM Group Ltd. do?

BGM Group Ltd. is a Cayman Islands holding company that operates as a pharmaceutical and chemical company through its subsidiaries and variable interest entity in China.

Company

About BGM Group Ltd.

BGM Group Ltd. is a Cayman Islands holding company that operates as a pharmaceutical and chemical company through its subsidiaries and variable interest entity in China. It specializes in manufacturing and distributing active pharmaceutical ingredients, traditional Chinese medicine derivatives, and related products for animal husbandry, human health, and agricultural applications. Key offerings include oxytetracycline products such as tablets and APIs used in treating diseases in livestock and humans; licorice-based medicines and extracts for pharmaceutical formulations; heparin sodium preparations for cardiovascular and hemodialysis treatments; antibacterial pastes for skin conditions; sausage casings; and organic fertilizers to enhance crop yields and soil quality. The company also focuses on AI applications, intelligent robots, algorithmic computing, cloud computing, and biopharmaceuticals, particularly through platforms like DuXiaoBao for insurance sales, underwriting, claims processing, and customer service in the insurance sector. BGM Group Ltd. integrates AI-driven solutions across its operations to optimize pharmaceutical manufacturing and supply chains. Founded in 2019 and based in Chengdu, China, it serves global markets in healthcare, technology, and agriculture.

CEO Mr. Chen Xin · 298 employees · China · https://www.bgmgroupltd.com